Hope Charities is excited to announce that Hope Conference 2024 will be held in Orlando, Florida on November 7-9th! Please save the date and plan to join us for a memorable time of learning, community building, and family fun. Registration and applications for travel scholarships will be opening soon, so be on the lookout for future emails with more details. We can’t wait to celebrate our 15th year of Hope Charities in Florida with our bleeding disorders family! BEQVEZ™ (fidanacogene elaparvovec-dkzt) Approval Granted by FDAOn April 25, 2024, Pfizer announced that the United States (U.S.) Food and Drug Administration (FDA) approved BEQVEZ™ (fidanacogene elaparvovec-dkzt) injection, for intravenous infusion. BEQVEZ is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who:
BEQVEZ™ (fidanacogene elaparvovec-dkzt) approved product labeling can be found here: BEQVEZ (fidanacogene elaparvovec-dkzt) U.S. Physician Prescribing Information |
Hope Charities
|